CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 28, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Deutsche Bank 33rd Annual Health Care Conference, which is being held on May 5-7, 2008 in Boston, Massachusetts. Curis' presentation will take place on Monday, May 5th at 12:00 p.m. Eastern Daylight Time.
Daniel R. Passeri, MSc., J.D., Curis' President and CEO, will provide a presentation that includes an overview of the status of GDC-0449, which is an orally-administered small molecule inhibitor of the Hedgehog pathway that our collaborator Genentech is currently preparing for phase II clinical testing. Mr. Passeri will also discuss CUDC-101 and Curis' other targeted cancer programs in addition to other corporate activities. There will also be a corresponding webcast of the presentation, which can be accessed by visiting:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CRIS&item_id=1836257
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
SOURCE: Curis, Inc.